TQJ230 — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-06-30 in 8d
ESTIMATED |
READOUT
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Maj
Phase 3 · Cardiovascular Disease and Lipoprotein(a) |
NVS NOVARTIS AG | TQJ230 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|